Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Date:10/1/2010

es to be approved by the U.S. Food and Drug Administration for the treatment of asymptomatic or minimally symptomatic metastatic castration resistant (hormone refractory) prostate cancer.

PROVENGE Important Safety Information

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry with a target enrollment of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.PROVENGE.com or call Dendreon ON CALL at 1-877-336-3736.

About Active Cellular Immunotherapy

PROVENGE is classified by the FDA as an autologous ce
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 According ... Vaccines Market - Growth, Trends & Forecasts (2015-2020) , ... to be worth US$ 2.85 billion by the end ... being the largest market globally accounting for more than ... for Therapeutic Vaccines is expected to grow at a ...
(Date:7/28/2015)... (NYSE: EW ), the global leader in the ... net income for the quarter ended June 30, 2015 of ... income on a non-GAAP basis was $124.4 million, or ... share in the prior year period. In the year ... share, which included a $750 million payment to Edwards ...
(Date:7/28/2015)... July 28, 2015  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $600.1 million, or ... as detailed in Table 4, were $1.44 for the ... clear many companies across healthcare are validating the need ... Chief Executive Officer. "But, what matters most is how ...
Breaking Medicine Technology:New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 2New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 3Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
... CVS Caremark (NYSE: CVS ) today ... of President for Accordant Health Services, a CVS Caremark ... for people with rare chronic conditions.  Murphy is charged ... with its specialty pharmacy programs and new focus on ...
... Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology ... Steven A. Rosenberg, M.D., Ph.D., Chief of the ... joined the Company,s Scientific and Medical Advisory Board. ... the Uniformed Services University of Health Sciences and ...
Cached Medicine Technology:CVS Caremark Appoints Kevin Murphy President of Accordant Business 2Genesis Biopharma's Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI 2Genesis Biopharma's Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI 3Genesis Biopharma's Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI 4
(Date:7/29/2015)... ... 29, 2015 , ... One may not expect to encounter a kickball game ... exactly what was happening on the campus of Piedmont Crossing , a local ... Kids Only , a five-star childcare center which operates on the same campus. ...
(Date:7/29/2015)... Orange County, CA (PRWEB) , ... July 29, 2015 , ... ... xylitol-based mouthwashes in a variety of gourmet flavors. , Nature’s Artisan was founded by ... in the Post-Baccalaureate program at the UCLA School of Dentistry. Tina was amazed when ...
(Date:7/28/2015)... ... ... Talking About Your Product Pipeline:, How FDA and SEC Regulate Life Sciences ... http://www.fdanews.com/productpipeline , When a company has a product in development, whether drug, device ... regulated by the FDA. , At the same time, the SEC requires that information ...
(Date:7/28/2015)... ... ... City Sports, a specialty sports retailer and a premiere destination for dedicated athletes ... Hanaka, who has served on the Board of Directors for City Sports since 2008 ... has had previous tenures as Chairman and CEO of Golfsmith International Holdings, Inc., Chairman ...
(Date:7/28/2015)... ... July 29, 2015 , ... The insurance telematics or ... This would allow insurers to access the on-board vehicle data and better understand customer ... it comes to sharing vehicle data. However times are changing and automakers realize that ...
Breaking Medicine News(10 mins):Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 2Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 3Health News:North Carolina Retirement Community Re-Launches Intergenerational Programming with Onsite Daycare Center 4Health News:Discover a New Take on Oral Care with Nature’s Artisan Gourmet Mouthwashes 2Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 4Health News:City Sports Names Marty Hanaka CEO 2Health News:General Motors Engaging Insurance Partners for the Connected Car 2Health News:General Motors Engaging Insurance Partners for the Connected Car 3
... , THURSDAY, Aug. 4 (HealthDay News) -- A growing number ... the clot-busting drug tissue plasminogen activator (tPA) to treat stroke ... An ischemic stroke is caused by blocked blood flow to ... residents who say they,re comfortable using tPA rose from 73 ...
... for most people means time spent outdoors, which could ... diseases, such as "rickettsial diseases" infectious diseases spread ... ticks and mites. Now a $1.6 million grant ... an entomologist at the University of California, Riverside to ...
... of Cardiology has issued the following statement today: ... the early termination of the PALLAS trial (a randomised ... atrial fibrillation and cardiovascular risk) because of adverse outcomes ... the Management of Atrial Fibrillation (AF) recommend the use ...
... doubles healthcare costs associated with the disease and threatens ... according to researchers at National Jewish Health. The research ... Archives of Allergy, Asthma & Immunology that children with ... days of school each year, compared to 2 or ...
... -- Women with the eating disorders anorexia and bulimia may ... a new study has found. U.K. researchers asked 11,088 ... of gestation. Of those women, 171 (1.5 percent) had anorexia ... bulimia, and another 82 (0.7 percent) had experienced both conditions. ...
... Warburton and Dr Gareth Barker in the University,s School of Physiology ... has investigated why we can recognise faces much better if we ... them in the first place. The study found that when ... face, occurred in a particular place, or at a particular time, ...
Cached Medicine News:Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:UC Riverside entomologist to study diseases transmitted by ticks 2Health News:UC Riverside entomologist to study diseases transmitted by ticks 3Health News:ESC announces review of Atrial Fibrillation Guidelines 2Health News:Poorly controlled asthma costly 2Health News:Eating Disorders Can Harm Women's Fertility 2Health News:Have we met before? Scientists show why the brain has the answer 2
Ideal for abdominal, hip, thigh and knee procedures....
Body Suit w/Bra above knee...
Gynecomastia Vest...
Male Compression Vest, Front Closure...
Medicine Products: